<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248430</url>
  </required_header>
  <id_info>
    <org_study_id>1838.00</org_study_id>
    <secondary_id>FHCRC-1838.00</secondary_id>
    <secondary_id>CDR0000430694</secondary_id>
    <nct_id>NCT00248430</nct_id>
  </id_info>
  <brief_title>Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer</brief_title>
  <official_title>A Phase I-II Trial of Adoptive Immunotherapy Using Haploidentical, Related Donor-Lymphocyte Infusions and IL-2 After Autologous Stem Cell Transplantation for Advanced Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing. An&#xD;
      autologous stem cell transplant using the patient's stem cells may be able to replace&#xD;
      blood-forming cells that were destroyed by chemotherapy. Giving white blood cells from a&#xD;
      donor may help the patient's body destroy any remaining cancer cells. Interleukin-2 may&#xD;
      stimulate the white blood cells to kill cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of donor white blood cell&#xD;
      infusions and interleukin-2 and to see how well they work in treating patients who are&#xD;
      undergoing an autologous stem cell transplant for relapsed advanced lymphoid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility and toxicity of haploidentical related donor lymphocyte&#xD;
           infusions (DLI) and interleukin-2, in terms of acute graft-versus-host-disease, graft&#xD;
           failure, and transplant-related mortality, in patients with relapsed advanced lymphoid&#xD;
           malignancies undergoing autologous stem cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the extent, degree, and duration of donor chimerism in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine, preliminarily, activity of haploidentical DLI, as measured by complete&#xD;
           response rate, in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive high-dose melphalan IV over 15-60 minutes on day -2 and undergo autologous&#xD;
      stem cell transplantation on day 0. Patients receive haploidentical related donor lymphocyte&#xD;
      infusions (DLI) IV on days 1, 5*, and 10* and interleukin-2 (IL-2) IV continuously on days&#xD;
      1-12.&#xD;
&#xD;
      NOTE: *DLI are not administered on days 5 or 10 if grade 3 or 4 graft-versus-host disease is&#xD;
      present&#xD;
&#xD;
      After completion of study treatment, patients are followed monthly for 3 months and then&#xD;
      every 3-12 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent, degree, and duration of donor chimerism</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following advanced lymphoid malignancies:&#xD;
&#xD;
               -  Multiple myeloma, meeting both of the following criteria:&#xD;
&#xD;
                    -  Deletion of chromosome 13&#xD;
&#xD;
                    -  Elevated pre-transplant lactic dehydrogenase&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
                    -  Failed ≥ 2 prior conventional chemotherapy regimens, including fludarabine&#xD;
&#xD;
               -  Small lymphocytic lymphoma&#xD;
&#xD;
               -  Follicular non-Hodgkin's lymphoma&#xD;
&#xD;
                    -  Received ≥ 3 prior conventional chemotherapy regimens&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
                    -  Received ≥ 3 prior conventional chemotherapy regimens&#xD;
&#xD;
          -  Predicted poor outcome and relapsed disease after undergoing autologous stem cell&#xD;
             transplantation ≥ 6 months ago&#xD;
&#xD;
          -  Measurable disease, defined as any evidence of disease by scans or blood or urine&#xD;
             analysis&#xD;
&#xD;
          -  At least 8 x 10^6 autologous CD34-positive cells/kg available for transplantation&#xD;
&#xD;
               -  Stem cell mobilization allowed&#xD;
&#xD;
          -  Haploidentical related donor available&#xD;
&#xD;
               -  Sex-mismatched&#xD;
&#xD;
               -  Identical for 1 HLA haplotype AND mismatched for ≥ 1 HLA-A, -B, -C, or DRB1 locus&#xD;
                  of the unshared haplotype&#xD;
&#xD;
               -  No HLA-identical related or unrelated donor available&#xD;
&#xD;
          -  Not eligible for first-line autologous stem cell transplantation on protocol&#xD;
             FHCRC-1368.00, FHCRC-1366.00, FHCRC-1461.00, or FHCRC-1595.00&#xD;
&#xD;
          -  No bulky disease, defined as total volume of all measurable tumor &gt; 500 cc&#xD;
&#xD;
          -  No CNS disease resistant to therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 69&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests or liver enzymes ≤ 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 45%&#xD;
&#xD;
          -  No symptomatic cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV Negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent contrast dye during and for 3 weeks after completion of interleukin-2&#xD;
             administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William I. Bensinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>graft versus host disease</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

